

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Rat Anti-CD8a Monoclonal Antibody, FITC Conjugated, Clone 53-6.7

RRID:AB_394568

Type: Antibody

Proper Citation

BD Biosciences Cat# 553030, RRID:AB_394568

Antibody Information

URL: http://antibodyregistry.org/AB_394568

Proper Citation: BD Biosciences Cat# 553030, RRID:AB_394568

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Rat Anti-CD8a Monoclonal Antibody, FITC Conjugated, Clone 53-6.7

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: 53-6.7

Antibody ID: AB_394568

Vendor: BD Biosciences

Catalog Number: 553030

Record Creation Time: 20231110T044633+0000

Record Last Update: 20260901T002631+0000

Ratings and Alerts

No rating or validation information has been found for Rat Anti-CD8a Monoclonal Antibody, FITC Conjugated, Clone 53-6.7.

No alerts have been found for Rat Anti-CD8a Monoclonal Antibody, FITC Conjugated, Clone 53-6.7.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lopez-Lago MA, et al. (2026) Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med (New York, N.Y.), 7(7), 101149.

Zhou J, et al. (2026) Gut-derived succinic acid potentiates high-altitude-related spermatogenesis dysfunction. Cell host & microbe, 34(1), 52.

Adan-Villaescusa E, et al. (2026) Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma. Cell reports. Medicine, 7(4), 102717.

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. Cancer cell.

Dong Z, et al. (2026) Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. Cell host & microbe.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer cell.

Ghosh A, et al. (2025) Potentiation of noncanonical NF- κ B signaling and marginal zone B cell expansion by CARD11-mediated regulation of p100 processing. Cell reports, 44(12), 116616.

Liu L, et al. (2025) Revealing the role of cancer-associated fibroblast senescence in prognosis and immune landscape in pancreatic cancer. iScience, 28(1), 111612.

Li C, et al. (2025) Integrin CD103 expression in naive CD8⁺ T cells promotes cytokine-driven acquisition of memory phenotype and effector function. Immunity.

Bednarz A, et al. (2025) Cobalt protoporphyrin IX induces transient, dose- and time-dependent granulocyte mobilization with mild metabolic effects in mice. Pharmacological reports : PR, 77(5), 1295.

Bresesti C, et al. (2025) Reprogramming liver metastasis-associated macrophages toward an anti-tumoral phenotype through enforced miR-342 expression. *Cell reports*, 44(5), 115592.

Zhao CN, et al. (2025) *Phocaeicola vulgatus* induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production. *Cell reports. Medicine*, 102370.

Luan Y, et al. (2025) IgG2c subclass dominance drives fatal lupus-like nephritis via Fc γ R and complement activation. *Cell reports*, 45(1), 116775.

Fu Y, et al. (2025) The low-dose CHK1 inhibitor prexasertib triggers VDAC1 dephosphorylation to activate mtDNA-STING signaling and synergize immunotherapy. *Cell reports*, 44(5), 115605.

Nagai M, et al. (2024) Sugar and arginine facilitate oral tolerance by ensuring the functionality of tolerogenic immune cell subsets in the intestine. *Cell reports*, 43(7), 114490.

Xie W, et al. (2024) Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periostin. *Cell metabolism*, 36(6), 1269.

Liu L, et al. (2024) Oncolytic bacteria VNP20009 expressing IFN γ inhibits melanoma progression by remodeling the tumor microenvironment. *iScience*, 27(4), 109372.

Chen J, et al. (2024) Intestinal microbiota imbalance resulted by anti-Toxoplasma gondii immune responses aggravate gut and brain injury. *Parasites & vectors*, 17(1), 284.

Beck JD, et al. (2024) Long-lasting mRNA-encoded interleukin-2 restores CD8 $^{+}$ T cell neoantigen immunity in MHC class I-deficient cancers. *Cancer cell*.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8 $^{+}$ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.